Clinical trials: Breast Cancer, Breast Neoplasms
Breast Cancer, Radiotoxicity
HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody
To evaluate the safety, dosimetry and efficacy of 99mTc/188Re labeled anti-HER2-single domain antibody (Product Code Name: 99mTc-NM-02 and 188Re-NM-02) SPECT/CT imaging of HER2 expression and radionuclide therapy in Breast…
- Trial name
- NCT04674722
- Testing
- Injection of 99mTc-NM-02, Injection of 188Re-NM-02
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Solid Tumor, High-Risk Cancer
A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations
This study was designed to evaluate the efficacy and safety of Extimia® (INN - empegfilgrastim) in reducing the frequency, duration of neutropenia, the incidence of febrile neutropenia and infections caused by febrile neutropenia…
- Conditions
- Solid Tumor, High-Risk Cancer, Breast Cancer, Gastrointestinal Cancer
- Trial name
- Def_Special (NCT04905329)
- Testing
- Empegfilgrastim
- Where
- 3 sites in Russia
- Volunteers
- 285 people
- Sponsor
- Moscow Clinical Scientific Center
Breast Neoplasms
A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer
CI-1033 is an experimental drug that acts as an inhibitor of erbB (EGFR) receptors, which may be involved in tumor growth. The primary objective of this study is to assess the antitumor activity of CI-1033 in patients with…
- Trial name
- NCT00051051
- Testing
- CI-1033
- Where
- 66 sites in United States, Belgium and 7 more
- Volunteers
- 168 people
- Sponsor
- Pfizer
Breast Cancer
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004175
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- 4 sites in United States
- Sponsor
- Northwestern University
Chronic Pain
Investigation of the Pain Relieving Properties of Lipotransplantation After Treatment for Breast Cancer
Background In Denmark, breast cancer is the most common fatal cancer in women with more than 4700 new cases annually. Unfortunately, up to 60% of women who are treated surgically for breast cancer, will experience chronic pain as…
- Trial name
- NCT01888419
- Testing
- Lipotransplantation
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- Aarhus University Hospital
Cancer, Pain
Improving Cancer Pain Management Through Self-Care
This study will test two different doses of a psychoeducational intervention to improve cancer pain management. In addition, the study will determine if the changes in pain management behaviors that the patients and family…
- Trial name
- NCT00708019
- Testing
- PRO-SELF PLUS Pain Management Program
- Where
- 2 sites in United States
- Volunteers
- 185 people
- Sponsor
- University of California, San Francisco
Breast Cancer
Adjuvant Ultra-Hypofractionated vs Hypofractionated Radiotherapy for Early Breast Cancer
breast-conserving surgery. One group receives ultra-hypofractionated radiotherapy (26 Gy in 5 sessions over 1 week), while the other group receives hypofractionated radiotherapy (40 Gy in 15 sessions over 3 weeks).
- Trial name
- UHF vs HF-EBC (NCT07274800)
- Testing
- Adjuvant Ultra hypofractionation radiotherapy, Adjuvant Hypofarctionated radiotherapy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Zagazig University
Breast Cancer
Psychosexuological Interventions to Support Sexual Function in Breast Cancer Patients
Prospective pilot study on the feasibility and efficacy of a brief psychosexual support intervention in breast cancer patients undergoing hormonal therapies for at least 6 months.
- Trial name
- NCT06327607
- Testing
- Control Group, Psychosexological intervention
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- European Institute of Oncology
Cancer
Objective Flap Assessment During Reconstructive Surgery
The main purpose of this study is to test the ergonomics of an investigational imaging system that can take pictures of blood vessels under the skin.
- Trial name
- NCT00952107
- Testing
- FLARE imaging system
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Beth Israel Deaconess Medical Center
Breast Cancer
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
Trial to optimize neoadjuvant therapy for HER overexpression and co-expressing of hormone receptors(ER and/or PR) breast cancer (HEr2+/HR+).
- Trial name
- ADAPT; T-DM1 (NCT01745965)
- Testing
- T-DM1, Trastuzumab
- Where
- 2 sites in Germany
- Volunteers
- 380 people
- Sponsor
- Women's Cancer Study Group GmbH
Breast Cancer
A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer
This study analyses the efficacy and safety of amlotinib as a study drug in the treatment of HER-2 negative advanced breast cancer in the real world, including the number of treatment lines, monotherapy, combination therapy, and…
- Trial name
- NCT06340165
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 153 people
- Sponsor
- The First Hospital of Jilin University
Edema, Erythema
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
This phase II trial studies how well pembrolizumab works in treating patients with stage IV inflammatory breast cancer or triple-negative breast cancer that has spread to other places in the body (metastatic) or has come back…
- Conditions
- Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative
- Trial name
- NCT02411656
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Neoplasms
Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer
This is a feasibility study to examine combination therapy with Trastuzumab (T), Cyclophosphamide (CY), and an allogeneic GM-CSF-secreting whole cell breast cancer vaccine in patients with Stage IV HER-2/neu-overexpressing breast…
- Trial name
- NCT00399529
- Testing
- Allogeneic GM-CSF-secreting breast cancer vaccine, Trastuzumab, Cyclophosphamide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Under- and Overdiagnosis in BreastScreen Norway
This PhD project will describe tumour characteristics and survival associated with of under- and overdiagnosed breast cancers, the rate of overdiagnosis in BreastScreen Norway, and whether women and family doctors are aware of…
- Trial name
- NCT03852953
- Testing
- Under- or overdiagnosed cancer, Screening
- Where
- Norway
- Volunteers
- 3,915 people, healthy volunteers welcome
- Sponsor
- Norwegian Institute of Public Health
Advanced Breast Cancer
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
The purpose of this study was to determine the safety of alpelisib plus fulvestrant in men and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or…
- Trial name
- ALPINIST (NCT05631795)
- Testing
- Alpelisib, Fulvestrant
- Where
- 12 sites in India
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Breast Cancer, Hormone Receptor Positive
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
This phase II trial studies the side effects of palbociclib when given together with fulvestrant or tamoxifen citrate in treating patients with hormone receptor positive breast cancer that has spread from where it started to…
- Trial name
- NCT02384239
- Testing
- Palbociclib, Tamoxifen, Fulvestrant
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Francisco
Breast Cancer
Dissecting the Pathways of Therapy Resistance in Early Breast Cancer
Within the 1st step MINDACT patients who have already relapsed will be asked to participate. For these patients a biopsy of the metastasis should have been taken.
- Trial name
- MINDACTRelapse (NCT04995575)
- Testing
- collection of the biopsy, blood samples
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 31 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Male Breast Cancer
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
Tipifarnib may stop the growth of breast cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT00470301
- Testing
- tipifarnib, paclitaxel, doxorubicin
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients
This phase I/II study is designed to compare different treatment schedules of a personalized anti-cancer vaccine protocol which combines the cryoablation of a selected metastatic lesion with intra-tumor immunotherapy.
- Trial name
- MBC (NCT02018419)
- Testing
- AlloStim, Cryoablation
- Where
- United States
- Sponsor
- Mirror Biologics, Inc.
Metastatic Breast Cancer
Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients
Breast cancer is one of the most prevalent cancers among women, and represents 20 - 25% of all female cancers. Despite earlier diagnosis and improvement in adjuvant therapies, some patients will present metastatic recurrence.
- Trial name
- FUMANCE (NCT02383030)
- Testing
- Fulvestrant
- Where
- 20 sites in Italy
- Volunteers
- 156 people
- Sponsor
- Consorzio Oncotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.